Getting personal with neoantigen-based therapeutic cancer vaccines.
about
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyDendritic Cells in Oncolytic Virus-Based Anti-Cancer TherapyRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondImmunotherapy advances for glioblastomaHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionSystematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.New Immunotherapy Strategies in Breast Cancer.Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition.Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal MesotheliomaMonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch RepairIdentification of immunotherapeutic targets by genomic profiling of rectal NET metastases.Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?HLA-binding properties of tumor neoepitopes in humans.Evolving role of tumor antigens for future melanoma therapies.Monitoring immune responses in the tumor microenvironment.Synthetic biology in cell-based cancer immunotherapy.Principles of immunology and its nuances in the central nervous system.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.An immunogenic personal neoantigen vaccine for patients with melanoma.Multifunctional nanoparticles for cancer immunotherapy.Novel Therapies in Development for Metastatic Colorectal Cancer.Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Genomic Approaches to Understanding Response and Resistance to Immunotherapy.Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Interaction of molecular alterations with immune response in melanoma.Boosting leukemia-specific T cell responses in patients following stem cell transplantation.Personal neoantigen cancer vaccines: The momentum builds.Antigen-specific culture of memory-like CD8 T cells for adoptive immunotherapy.Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination.Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.Mutation Drivers of Immunological Responses to Cancer.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Informatics for cancer immunotherapy.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
P2860
Q26745516-E7B43860-A967-4174-A43D-2AAA1F90FB34Q26774345-08ABA633-C173-44CB-8122-13B6BA916F02Q26861563-D11B0C3C-FD3E-41F0-B1F9-F2345891C2EFQ26866513-89EBD7DA-A102-4EA7-A936-BE0F14519C6EQ27021570-E4D38504-DC0D-4F11-915D-5602813165F6Q28082487-98EA5ABE-5C68-44EF-B193-1B1874C99B86Q33917224-C662D6AE-4482-40FC-B261-4E8259E6A933Q34549227-980C1D9C-8AC8-4B52-A4D5-2E495F88FE52Q35140015-20B35074-186F-4FE6-840B-ED81F7C4AD38Q35533586-0524B625-7599-47C5-84DA-2BEC1AFAED7EQ36939300-D5CA9E1E-CD05-4E4E-BA84-627AF8EE98C5Q37253354-8ABB093C-F10B-44C9-8218-FB413ADB4F1FQ37477282-569ACF23-A5DD-40CE-8E1D-3D38D1341AA3Q37516937-DBE148E5-FF9C-4929-90BA-11E1CB1CCC53Q38209294-50127B68-4196-4DE6-B7BA-00FA76E4158AQ38217357-9B1D3ED0-38B4-4C0E-BA5B-F3F259D0B8BBQ38232855-80F0B4C1-D869-40B6-895E-D2D521882691Q38380080-98060C3F-A9B9-419A-B40B-D10008B7858AQ38531361-D50765D6-D299-441C-BED4-560B7D4C2018Q38620084-E556B053-1B6E-45E1-92EC-42CD0EEEE251Q38673585-9ABCD8EB-46BD-435C-9C42-241873CDD04DQ38692859-66CD0C81-1EF7-4656-BA2C-6773DF4D25A2Q38744042-1F4E343F-8487-4CCF-B10D-DD8923FB7493Q38800472-D889022D-DB03-40BA-9107-E9EC0B9B8CEDQ38810264-5C288378-45AD-4E76-B38A-9386A6BCE21BQ38971262-4F20F90F-70E2-44A4-98E3-A7F6DF1759F3Q39092611-8D99405B-598C-477F-8F1F-A6047A61BF9AQ39107407-FC5ADC67-C559-40E3-BF64-652616A97340Q39243052-5BA66FDB-1129-46C8-B151-266EE493F300Q39329609-15804D07-8761-4702-A40F-721D2D520EAEQ41882563-3256CC19-A853-451D-AEE8-3D54058AFC21Q41985178-A2178FA7-135C-43DA-859E-F83AAB75231AQ42124330-4BFE9C6F-9D51-4552-8571-8AD2D62A33E7Q42177990-30985258-7074-4E05-9C79-E2D6A70CBCC5Q42821853-EE11A4E4-4E08-46B7-B819-00109F416EE4Q46217247-2A3578F1-9A6F-42E6-9E30-7DD5F86D38CEQ46898270-B43C5989-950D-459E-88EE-8D2D03A3B370Q47190955-000EFA5F-9D0D-498E-BFB0-10F35BE07C11Q47290509-246D3E04-8653-4E71-A7C4-E6CE9EBF05C6Q47621538-E83496D1-DBFE-4950-9993-500AE6DD3F2E
P2860
Getting personal with neoantigen-based therapeutic cancer vaccines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Getting personal with neoantigen-based therapeutic cancer vaccines.
@en
Getting personal with neoantigen-based therapeutic cancer vaccines.
@nl
type
label
Getting personal with neoantigen-based therapeutic cancer vaccines.
@en
Getting personal with neoantigen-based therapeutic cancer vaccines.
@nl
prefLabel
Getting personal with neoantigen-based therapeutic cancer vaccines.
@en
Getting personal with neoantigen-based therapeutic cancer vaccines.
@nl
P2093
P2860
P1476
Getting personal with neoantigen-based therapeutic cancer vaccines.
@en
P2093
Catherine J Wu
Edward F Fritsch
Todd A Carter
P2860
P356
10.1158/2326-6066.CIR-13-0022
P577
2013-04-07T00:00:00Z